全球RNA療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

RNA療法市場預計將從2025年的208.9億美元成長到2034年的348.7億美元，2026年至2034年的複合年成長率為5.86%。

在全球分子生物學和個人化醫療領域取得突破性進展的推動下，RNA療法市場正經歷著變革性成長。隨著疫苗研發的成功，包括mRNA疫苗和RNA干擾療法在內的RNA治療方法已廣受認可。製藥公司正增加對RNA平台的投資，以應對罕見疾病、腫瘤和遺傳性疾病，這進一步推動了市場的顯著擴張。

成長要素包括慢性病盛行率上升、遞送系統技術進步以及有利的法規結構。研發經費的增加以及生技公司與大型製藥公司之間的策略合作正在加速產品管線的開發。 mRNA技術的成功應用增強了投資者的信心，並促進了其在多種疾病領域的廣泛治療應用。

展望未來，RNA穩定技術和標靶遞送機制的持續創新將開闢新的治療途徑。臨床試驗的擴展和監管核准有望進一步驗證RNA治療方法的有效性。隨著精準醫療重要性的日益凸顯，RNA療法市場預計將經歷強勁的長期成長，並為下一代藥物的研發奠定基礎。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球RNA治療市場：依產品分類

• 市場分析、洞察與預測
• 疫苗
• 製藥

第5章 全球RNA治療市場：依類型分類

• 市場分析、洞察與預測
• mRNA治療藥物
• RNA干擾（RNAi）治療藥物
• 反義寡核苷酸（ASO）療法
• 其他治療方法

第6章：全球RNA治療市場：依適應症分類

• 市場分析、洞察與預測
• 感染疾病
• 罕見遺傳疾病/遺傳性疾病
• 其他跡象

第7章 全球RNA治療市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院和診所
• 研究設施

第8章 全球RNA療法市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 亞太其他地區
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Moderna Inc
  • Alnylam Pharmaceuticals Inc
  • Pfizer Inc
  • Novartis AG
  • Ionis Pharmaceuticals Inc
  • Sarepta Therapeutics Inc
  • Sanofi
  • Arrowhead Pharmaceuticals Inc
  • BioNTech SE
  • Orna Therapeutics
  • CRISPR Therapeutics
  • Silence Therapeutics
  • Astellas Pharma Inc
  • CureVac SE
  • Sirnaomics

The RNA Therapeutics Market size is expected to reach USD 34.87 Billion in 2034 from USD 20.89 Billion (2025) growing at a CAGR of 5.86% during 2026-2034.

The Global RNA Therapeutics Market is experiencing transformative growth driven by breakthroughs in molecular biology and personalized medicine. RNA-based treatments, including mRNA vaccines and RNA interference therapies, have gained widespread recognition following successful vaccine developments. Pharmaceutical companies are increasingly investing in RNA platforms to address rare diseases, oncology indications, and genetic disorders, fueling substantial market expansion.

Growth drivers include rising prevalence of chronic diseases, technological advancements in delivery systems, and supportive regulatory frameworks. Increasing research funding and strategic collaborations between biotech firms and pharmaceutical giants are accelerating pipeline development. The demonstrated success of mRNA technology has strengthened investor confidence and encouraged broader therapeutic applications across multiple disease categories.

Looking ahead, continuous innovation in RNA stabilization and targeted delivery mechanisms will unlock new treatment possibilities. Expansion of clinical trials and regulatory approvals is expected to further validate RNA-based solutions. As precision medicine gains prominence, the RNA therapeutics market is projected to witness strong long-term growth and become a cornerstone of next-generation drug development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Vaccines
• Drugs

By Type

• mRNA Therapeutics
• RNA Interference (RNAi) Therapeutics
• Antisense Oligonucleotide (ASO) Therapeutics
• Other Therapeutics

By Indication

• Infectious Diseases
• Rare Genetic Diseases/Hereditary Diseases
• Other Indications

By End User

• Hospitals and Clinics
• Research Settings

COMPANIES PROFILED

• Moderna Inc, Alnylam Pharmaceuticals Inc, Pfizer Inc, Novartis AG, Ionis Pharmaceuticals Inc, Sarepta Therapeutics Inc, Sanofi, Arrowhead Pharmaceuticals Inc, BioNTech SE, Orna Therapeutics, CRISPR Therapeutics, Silence Therapeutics, Astellas Pharma Inc, CureVac SE, Sirnaomics
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RNA THERAPEUTICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RNA THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. mRNA Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. RNA Interference (RNAi) Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Antisense Oligonucleotide (ASO) Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RNA THERAPEUTICS MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Rare Genetic Diseases/Hereditary Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RNA THERAPEUTICS MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals and Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Research Settings Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL RNA THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Type
  • 8.2.3 By Indication
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Type
  • 8.3.3 By Indication
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Type
  • 8.4.3 By Indication
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Type
  • 8.5.3 By Indication
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Type
  • 8.6.3 By Indication
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL RNA THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Moderna Inc
  • 10.2.2 Alnylam Pharmaceuticals Inc
  • 10.2.3 Pfizer Inc
  • 10.2.4 Novartis AG
  • 10.2.5 Ionis Pharmaceuticals Inc
  • 10.2.6 Sarepta Therapeutics Inc
  • 10.2.7 Sanofi
  • 10.2.8 Arrowhead Pharmaceuticals Inc
  • 10.2.9 BioNTech SE
  • 10.2.10 Orna Therapeutics
  • 10.2.11 CRISPR Therapeutics
  • 10.2.12 Silence Therapeutics
  • 10.2.13 Astellas Pharma Inc
  • 10.2.14 CureVac SE
  • 10.2.15 Sirnaomics